{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:12:44Z","timestamp":1794975164912,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T00:00:00Z","timestamp":1509408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T00:00:00Z","timestamp":1509408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chagas disease is caused by the protozoan parasite\n                    <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                    and affects 5\u20138 million people in Latin America. Although the nitroheterocyclic compound benznidazole has been the front-line drug for several decades, treatment failures are common. Benznidazole is a pro-drug and is bio-activated within the parasite by the mitochondrial nitroreductase TcNTR-1, leading to the generation of reactive metabolites that have trypanocidal activity. To better assess drug action and resistance, we sequenced the genomes of\n                    <jats:italic>T. cruzi<\/jats:italic>\n                    Y strain (35.5\u2009Mb) and three benznidazole-resistant clones derived from a single drug-selected population. This revealed the genome-wide accumulation of mutations in the resistant parasites, in addition to variations in DNA copy-number. We observed mutations in DNA repair genes, linked with increased susceptibility to DNA alkylating and inter-strand cross-linking agents. Stop-codon-generating mutations in\n                    <jats:italic>TcNTR-1<\/jats:italic>\n                    were associated with cross-resistance to other nitroheterocyclic drugs. Unexpectedly, the clones were also highly resistant to the ergosterol biosynthesis inhibitor posaconazole, a drug proposed for use against\n                    <jats:italic>T. cruzi<\/jats:italic>\n                    infections, in combination with benznidazole. Our findings therefore identify the highly mutagenic activity of benznidazole metabolites in\n                    <jats:italic>T. cruzi<\/jats:italic>\n                    , demonstrate that this can result in multi-drug resistance, and indicate that vigilance will be required if benznidazole is used in combination therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-14986-6","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T05:32:57Z","timestamp":1508909577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole"],"prefix":"10.1038","volume":"7","author":[{"given":"M\u00f4nica C.","family":"Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody","family":"Phelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1755-2819","authenticated-orcid":false,"given":"Arnab","family":"Pain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8985-9265","authenticated-orcid":false,"given":"Taane G.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4305-5258","authenticated-orcid":false,"given":"John M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,31]]},"reference":[{"key":"14986_CR1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1056\/NEJMra1410150","volume":"373","author":"C Bern","year":"2015","unstructured":"Bern, C. Chagas\u2019 Disease. N. Engl. J. Med. \n                           373, 456\u2013466 (2015).","journal-title":"N. Engl. J. Med."},{"key":"14986_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11908-012-0259-3","volume":"14","author":"JA P\u00e9rez-Molina","year":"2012","unstructured":"P\u00e9rez-Molina, J. A., Norman, F. & L\u00f3pez-V\u00e9lez, R. Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment. Curr. Infect. Dis. Rep. \n                           14, 263\u2013274 (2012).","journal-title":"Curr. Infect. Dis. Rep."},{"key":"14986_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00281-015-0481-9","volume":"37","author":"RL Tarleton","year":"2015","unstructured":"Tarleton, R. L. CD8\u2009+\u2009T cells in Trypanosoma cruzi infection. Semin. Immunpath. \n                           37, 233\u2013238 (2015).","journal-title":"Semin. Immunpath."},{"key":"14986_CR4","doi-asserted-by":"publisher","first-page":"683230","DOI":"10.1155\/2014\/683230","volume":"2014","author":"E Cunha-Neto","year":"2014","unstructured":"Cunha-Neto, E. & Chevillard, C. Chagas disease cardiomyopathy: immunopathology and genetics. Mediators of Inflammation \n                           2014, 683230 (2014).","journal-title":"Mediators of Inflammation"},{"key":"14986_CR5","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","volume":"370","author":"I Molina","year":"2014","unstructured":"Molina, I. et al. Randomized trial of posaconazole and benznidazole for chronic Chagas disease. N. Engl. J. Med. \n                           370, 1899\u20131908 (2014).","journal-title":"N. Engl. J. Med."},{"key":"14986_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","volume":"373","author":"CA Morillo","year":"2015","unstructured":"Morillo, C. A. et al. Randomized trial of benznidazole for chronic Chagas\u2019 cardiomyopathy. N. Engl. J. Med. \n                           373, 1295\u20131306 (2015).","journal-title":"N. Engl. J. Med."},{"key":"14986_CR7","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1073\/pnas.0711014105","volume":"105","author":"SR Wilkinson","year":"2008","unstructured":"Wilkinson, S. R., Taylor, M. C., Horn, D., Kelly, J. M. & Cheeseman, I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. USA \n                           105, 5022\u20135027 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"14986_CR8","doi-asserted-by":"crossref","unstructured":"Wilkinson, S. R. & Kelly, J. M. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev. Molec. Med\n                           . 11, e31 pp1-24 (2009).","DOI":"10.1017\/S1462399409001252"},{"key":"14986_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/infdis\/jis331","volume":"206","author":"AM Mejia","year":"2012","unstructured":"Mejia, A. M. et al. Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population. J. Infect. Dis. \n                           206, 220\u2013228 (2012).","journal-title":"J. Infect. Dis."},{"key":"14986_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.exppara.2004.07.001","volume":"108","author":"D Villarreal","year":"2004","unstructured":"Villarreal, D., Barnab\u00e9, C., Sereno, D. & Tibayrenc, M. Lack of correlation between in vitro susceptibility to benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease. Exp. Parasitol. \n                           108, 24\u201331 (2004).","journal-title":"Exp. Parasitol."},{"key":"14986_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/tmi.12014","volume":"18","author":"AP Teston","year":"2013","unstructured":"Teston, A. P. et al. In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon. Trop. Med. Internat. Health \n                           18, 85\u201395 (2013).","journal-title":"Trop. Med. Internat. Health"},{"key":"14986_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.actatropica.2016.11.033","volume":"167","author":"MT Oliveira","year":"2017","unstructured":"Oliveira, M. T. et al. TcI, TcII and TcVI Trypanosoma cruzi samples from Chagas disease patients with distinct clinical forms and critical analysis of in vitro and in vivo behavior, response to treatment and infection evolution in murine model. Acta Tropica \n                           167, 108\u2013120 (2017).","journal-title":"Acta Tropica"},{"key":"14986_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0731-7085(02)00081-X","volume":"29","author":"MA La-Scalea","year":"2002","unstructured":"La-Scalea, M. A., Serrano, S. H., Ferreira, E. I. & Brett, A. M. Voltammetric behavior of benznidazole at a DNA-electrochemical biosensor. J. Pharm. Biomed. Anal. \n                           29, 561\u2013568 (2002).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"14986_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/em.21839","volume":"55","author":"MA Raj\u00e3o","year":"2014","unstructured":"Raj\u00e3o, M. A. et al. Unveiling benznidazole\u2019s mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi. Environ. Mol. Mutagen. \n                           55, 309\u2013321 (2014).","journal-title":"Environ. Mol. Mutagen."},{"key":"14986_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/AAC.05135-11","volume":"56","author":"BS Hall","year":"2012","unstructured":"Hall, B. S. & Wilkinson, S. R. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob. Agents Chemother. \n                           56, 115\u2013123 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"14986_CR16","doi-asserted-by":"publisher","first-page":"e2844","DOI":"10.1371\/journal.pntd.0002844","volume":"22","author":"A Trochine","year":"2014","unstructured":"Trochine, A., Creek, D. J., Faral-Tello, P., Barrett, M. P. & Robello, C. Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. PLoS Negl. Trop. Dis. \n                           22, e2844 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"14986_CR17","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/cmi.12297","volume":"16","author":"MD Lewis","year":"2014","unstructured":"Lewis, M. D. et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell. Microbiol. \n                           16, 1285\u20131300 (2014).","journal-title":"Cell. Microbiol."},{"key":"14986_CR18","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/cmi.12584","volume":"18","author":"MD Lewis","year":"2016","unstructured":"Lewis, M. D., Fortes Francisco, A., Taylor, M. C., Jayawardhana, S. & Kelly, J. M. Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy. Cell. Microbiol. \n                           18, 1429\u20131443 (2016).","journal-title":"Cell. Microbiol."},{"key":"14986_CR19","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1128\/AAC.00520-15","volume":"59","author":"A Fortes Francisco","year":"2015","unstructured":"Fortes Francisco, A. et al. The limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging. Antimicrob. Agents Chemother. \n                           59, 4653\u20134661 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"14986_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molbiopara.2014.01.002","volume":"193","author":"MC Campos","year":"2014","unstructured":"Campos, M. C., Leon, L. L., Taylor, M. C. & Kelly, J. M. Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert. Mol. Biochem. Parasitol. \n                           193, 17\u201319 (2014).","journal-title":"Mol. Biochem. Parasitol."},{"key":"14986_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.1112631","volume":"309","author":"NM El-Sayed","year":"2005","unstructured":"El-Sayed, N. M. et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science \n                           309, 409\u2013415 (2005).","journal-title":"Science"},{"key":"14986_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1101\/gr.2895105","volume":"15","author":"SO Obado","year":"2005","unstructured":"Obado, S. O., Taylor, M. C., Wilkinson, S. R., Bromley, E. V. & Kelly, J. M. Functional mapping of a trypanosome centromere by chromosome fragmentation identifies a 16 kb GC-rich transcriptional \u201cstrand-switch\u201d domain as a major feature. Genome Res. \n                           15, 36\u201343 (2005).","journal-title":"Genome Res."},{"key":"14986_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-016-3037-z","volume":"17","author":"DB Weatherly","year":"2016","unstructured":"Weatherly, D. B., Peng, D. & Tarleton, R. L. Recombination-driven generation of the largest pathogen repository of antigen variants in the protozoan Trypanosoma cruzi. BMC Genomics \n                           17, 729 (2016).","journal-title":"BMC Genomics"},{"key":"14986_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.molbiopara.2008.03.007","volume":"160","author":"P Portal","year":"2008","unstructured":"Portal, P. et al. Multiple NADPH-cytochrome P450 reductases from Trypanosoma cruzi: Suggested role in drug resistance. Mol. Biochem. Parasitol. \n                           160, 42\u201351 (2008).","journal-title":"Mol. Biochem. Parasitol."},{"key":"14986_CR25","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1017\/S003118201300022X","volume":"140","author":"S Alsford","year":"2013","unstructured":"Alsford, S., Kelly, J. M., Baker, N. & Horn, D. Genetic dissection of drug resistance in trypanosomes. Parasitology \n                           140, 1478\u20131491 (2013).","journal-title":"Parasitology"},{"key":"14986_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.meegid.2015.01.030","volume":"31","author":"J Franco","year":"2015","unstructured":"Franco, J., Ferreira, R. C., Ienne, S. & Zingales, B. ABCG-like transporter of Trypanosoma cruzi involved in benznidazole resistance: gene polymorphisms disclose inter-strain intragenic recombination in hybrid isolates. Infect. Genet. Evol. \n                           31, 198\u2013208 (2015).","journal-title":"Infect. Genet. Evol."},{"key":"14986_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00232-016-9888-z","volume":"249","author":"C Reigada","year":"2016","unstructured":"Reigada, C. et al. Trypanosoma cruzi polyamine transporter: Its role on parasite growth and survival under stress conditions. J. Membr. Biol. \n                           249, 475\u2013481 (2016).","journal-title":"J. Membr. Biol."},{"key":"14986_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ab.2009.09.009","volume":"396","author":"BR Branchini","year":"2010","unstructured":"Branchini, B. R. et al. Red-emitting luciferases for bioluminescence reporter and imaging applications. Anal. Biochem. \n                           396, 290\u2013297 (2010).","journal-title":"Anal. Biochem."},{"key":"14986_CR29","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/jac\/dkv376","volume":"71","author":"S Wyllie","year":"2016","unstructured":"Wyllie, S. et al. Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei. J. Antimicrob. Chemother. \n                           71, 625\u2013634 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"14986_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","volume":"69","author":"CA Morillo","year":"2017","unstructured":"Morillo, C. A. et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: The STOP-CHAGAS trial. J. Am. Coll. Cardiol. \n                           69, 939\u2013947 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"14986_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ijantimicag.2012.08.002","volume":"40","author":"S Cencig","year":"2012","unstructured":"Cencig, S., Coltel, N., Truyens, C. & Carlier, Y. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome\u00ae in mice infected with Trypanosoma cruzi strains. Int. J. Antimicrob. Agents \n                           40, 527\u2013532 (2012).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"14986_CR32","doi-asserted-by":"publisher","first-page":"e2367","DOI":"10.1371\/journal.pntd.0002367","volume":"7","author":"L Diniz","year":"2013","unstructured":"Diniz, L. & de, F. et al. Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl. Trop. Dis. \n                           7, e2367 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"14986_CR33","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2016.12.016","volume":"69","author":"C Bern","year":"2017","unstructured":"Bern, C. A new epoch in antitrypanosomal treatment for Chagas disease. J. Am. Coll. Cardiol. \n                           69, 948\u2013950 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"14986_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/B978-0-12-385863-4.00004-6","volume":"75","author":"GI Lepesheva","year":"2012","unstructured":"Lepesheva, G. I., Villalta, F. & Waterman, M. R. Targeting Trypanosoma cruzi sterol 14\u03b1-demethylase (CYP51). Adv. Parasitol. \n                           75, 65\u201387 (2012).","journal-title":"Adv. Parasitol."},{"key":"14986_CR35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijpddr.2011.12.002","volume":"2","author":"FS Buckner","year":"2012","unstructured":"Buckner, F. S. & Urbina, J. A. Recent developments in sterol 14\u03b1-demethylase inhibitors for Chagas disease. Int. J. Parasitol. Drugs Drug Resist. \n                           2, 236\u2013242 (2012).","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"14986_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/13693786.2012.685767","volume":"51","author":"A Pratt","year":"2013","unstructured":"Pratt, A. et al. Evaluation of fungal-specific fluorescent labeled echinocandin probes as diagnostic adjuncts. Med. Mycol. \n                           51, 103\u2013107 (2013).","journal-title":"Med. Mycol."},{"key":"14986_CR37","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/infdis\/jit358","volume":"208","author":"P Campoli","year":"2013","unstructured":"Campoli, P. et al. Pharmacokinetics of posaconazole within epithelial cells and fungi: Insights into potential mechanisms of action during treatment and prophylaxis. J. Infect. Dis. \n                           208, 1717\u20131728 (2013).","journal-title":"J. Infect. Dis."},{"key":"14986_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.molbiopara.2005.12.001","volume":"146","author":"SM Murta","year":"2006","unstructured":"Murta, S. M. et al. Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Mol. Biochem. Parasitol. \n                           146, 151\u2013162 (2006).","journal-title":"Mol. Biochem. Parasitol."},{"key":"14986_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.actatropica.2006.10.004","volume":"100","author":"FB Nogueira","year":"2006","unstructured":"Nogueira, F. B. et al. Increased expression of iron-containing superoxide dismutase-A (TcFeSOD-A) enzyme in Trypanosoma cruzi population with in vitro-induced resistance to benznidazole. Acta Trop. \n                           100, 119\u2013132 (2006).","journal-title":"Acta Trop."},{"key":"14986_CR40","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1016\/0006-2952(87)90648-4","volume":"36","author":"A Zahoor","year":"1987","unstructured":"Zahoor, A., Lafleur, M. V., Knight, R. C., Loman, H. & Edwards, D. I. DNA damage induced by reduced nitroimidazole drugs. Biochem. Pharmacol. \n                           36, 3299\u20133304 (1987).","journal-title":"Biochem. Pharmacol."},{"key":"14986_CR41","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/BF01941187","volume":"44","author":"EG Diaz de Toranzo","year":"1998","unstructured":"Diaz de Toranzo, E. G., Castro, J. A., Franke de Cazzulo, B. M. & Cazzulo, J. J. Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi. Experientia \n                           44, 880\u2013881 (1998).","journal-title":"Experientia"},{"key":"14986_CR42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrc3342","volume":"12","author":"P Bouwman","year":"2012","unstructured":"Bouwman, P. & Jonkers, J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer \n                           12, 587\u2013598 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"14986_CR43","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature \n                           451, 1116\u20131120 (2008).","journal-title":"Nature"},{"key":"14986_CR44","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1590\/S0074-02762010000700014","volume":"105","author":"M Moreno","year":"2010","unstructured":"Moreno, M. et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Mem. Inst. Oswaldo Cruz \n                           105, 918\u2013924 (2010).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"14986_CR45","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1002\/j.1460-2075.1990.tb07462.x","volume":"9","author":"G Kendall","year":"1990","unstructured":"Kendall, G., Wilderspin, A. F., Ashall, F., Miles, M. A. & Kelly, J. M. Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase does not conform to the \u201chotspot\u201d topogenic signal model. EMBO J. \n                           9, 2751\u20132758 (1990).","journal-title":"EMBO J."},{"key":"14986_CR46","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1007\/s00436-013-3398-z","volume":"112","author":"MC Campos","year":"2013","unstructured":"Campos, M. C. et al. P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance. Parasitol. Res. \n                           112, 2341\u20132351 (2013).","journal-title":"Parasitol. Res."},{"key":"14986_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1087057114552623","volume":"20","author":"MD Lewis","year":"2015","unstructured":"Lewis, M. D., Fortes Francisco, A., Taylor, M. C. & Kelly, J. M. A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging. J. Biomolecular Screening \n                           20, 36\u201343 (2015).","journal-title":"J. Biomolecular Screening"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14986-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14986-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14986-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T07:58:01Z","timestamp":1671782281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14986-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,31]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["14986"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-14986-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,31]]},"assertion":[{"value":"15 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14407"}}